Last update 21 Nov 2024

Sonrotoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC49H59N7O7S
InChIKeyZQTKOYMWCCSKON-XKXNWSITSA-N
CAS Registry2383086-06-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPhase 3
CA
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
FR
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
TR
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
DE
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
IL
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
CN
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
ES
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
KR
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
PL
11 Nov 2023
Chronic Lymphocytic LeukemiaPhase 3
BR
11 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Chronic Lymphocytic Leukemia
IGHV | TP53mutation | del(17p)
112
(fnhjjkroyk) = dgezozejoh zfqlxvftqp (qumelxwwbh )
Positive
09 Dec 2024
(fnhjjkroyk) = hymyittzpa zfqlxvftqp (qumelxwwbh )
Phase 1/2
42
(xykkfqytev) = wvwmlhojzl tahrlaynvy (dpjkxuqhpv )
Positive
14 May 2024
Phase 1/2
39
(sqbiftvjsr) = bimrobnzha ekptpswkmk (nrmscutzgf )
Positive
14 May 2024
Phase 1
45
(judcpuneiz) = Any-grade treatment-emergent AEs (TEAEs) that occurred in ≥20% of patients wereCOVID-19 (n=12; 27%), contusion (n=12 [27%]), neutropenia (n=12 [27%]), diarrhea (n=11 [24%]), nausea(n=11 [24%]) and fatigue (n=11 [24%]) vmnfznsafk (gsgvslyedj )
Positive
14 May 2024
Phase 1
17
(lkcwaxjvyb) = occurred in ≥20% of patients who received sonrotoclax were anemia (n=6, 35%), COVID-19 (n=6, 35%), pyrexia (n=5, 29%), neutropenia (n=4, 24%), and pruritus(n=4, 24%). Anemia was the most common grade ≥3 TEAE (n=4; 24%). gitdsoupci (ilkdklfnzf )
Positive
14 May 2024
Phase 1
27
(cdxkpscdyf) = jhkczrhbja mptrueqpsw (sviribwxxj )
Positive
14 May 2024
zanubrutinib(320 mg QD or 160 mg BID) + sonrotoclax (80mg )
(cdxkpscdyf) = trozkaxiwi mptrueqpsw (sviribwxxj )
Phase 1
13
(lsadarswdb) = kzhdulgudm lfxzsaxivu (awccwiaani )
-
10 Dec 2023
Phase 1/2
94
(jqbicitsgh) = gqtbkxygxg dgoxemolin (bilynlwwsw )
-
09 Dec 2023
Phase 1
54
(vbmjohxzfx) = engipntjfx nejstmcaxz (jzvxbdbbiu )
-
08 Jun 2023
Phase 1
54
edbrwfrysx(lymdfdffry) = The monotherapy RP2D for R/R CLL/SLL was 320 mg/d. uqzjnkldso (vsgejgeslv )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free